Last reviewed · How we verify
LY3200882
At a glance
| Generic name | LY3200882 |
|---|---|
| Also known as | Capecitabine |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY3200882 in Participants With Solid Tumors (PHASE1)
- LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) (PHASE1, PHASE2)
- A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer (PHASE1, PHASE2)
- An Interaction Study of LY3200882 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3200882 CI brief — competitive landscape report
- LY3200882 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI